Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 20;24(6):1098.
doi: 10.3390/molecules24061098.

Computational Drug Design Applied to the Study of Metabotropic Glutamate Receptors

Affiliations
Review

Computational Drug Design Applied to the Study of Metabotropic Glutamate Receptors

Claudia Llinas Del Torrent et al. Molecules. .

Abstract

Metabotropic glutamate (mGlu) receptors are a family of eight GPCRs that are attractive drug discovery targets to modulate glutamate action and response. Here we review the application of computational methods to the study of this family of receptors. X-ray structures of the extracellular and 7-transmembrane domains have played an important role to enable structure-based modeling approaches, whilst we also discuss the successful application of ligand-based methods. We summarize the literature and highlight the areas where modeling and experiment have delivered important understanding for mGlu receptor drug discovery. Finally, we offer suggestions of future areas of opportunity for computational work.

Keywords: GPCR; allosteric modulator; homology model; ligand-based design; mGlu; mGluR; molecular dynamics; structure-based design; virtual screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Pie chart showing reported ligands for mGlu receptors in the Thomson Reuters Integrity database. The most explored are mGlu5, mGlu2, and mGlu1. Extracted on 29 January 2019 and compared with results from March 2017.
Figure 2
Figure 2
The structure of mGlu receptors: (a) Structure of the full length apo mGlu5 receptor homodimer showing the VFT, CRD, and 7TM domains (PDB 6N52); (b) X-ray structures of mGlu1 and mGlu5 receptor 7TMs showing the different depth of binding for NAMs. (c) Close up view of the X-ray structures of the 7TM domains showing the overlay of NAMs FITM (orange) and mavoglurant (magenta) bound at mGlu1 and mGlu5 receptors with several amino acids labelled.
Figure 3
Figure 3
Chemical structures of selected ligands for mGlu1 and mGlu5 receptors.
Figure 4
Figure 4
(a) The mGlu5 7TM showing amino acids identified from experimental mutagenesis as important for allosteric modulator activity, compared with (b) the overlap of the subsequent X-ray crystal structures of multiple mGlu5 receptor NAMs.
Figure 5
Figure 5
Origin of the functional effect of mGlu2 PAMs and mGlu2 NAMs. A combined experimental and computational study by Perez-Benito et al. [82] showed that PAMs and NAMs bind above the transmission switch but transmit a different conformational effect. Based on the modelling, amino acids in the transmission switch were proposed for experimental mutagenesis that confirmed their importance for receptor activation. Thus, validating a hypothesis of local allosteric modulator induced conformational changes that promote or block movements of amino acids responsible for functional activity, overall confirming the 7TM analogy with class A GPCRs.
Figure 6
Figure 6
Ligand-based approaches leading to identification of new mGlu2 PAMs. (a) The structural alignment and pharmacophore of selected mGlu2 receptor PAMs. (b) The electrostatic fields showing the similarity between pyridone and subsequent imidazopyridine and triazopyridine scaffolds.

Similar articles

Cited by

References

    1. Fagerberg L., Jonasson K., von Heijne G., Uhlén M., Berglund L. Prediction of the human membrane proteome. Proteomics. 2010;10:1141–1149. doi: 10.1002/pmic.200900258. - DOI - PubMed
    1. Pin J.-P., Galvez T., Prézeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol. Ther. 2003;98:325–354. doi: 10.1016/S0163-7258(03)00038-X. - DOI - PubMed
    1. Niswender C.M., Conn P.J. Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease. Annu. Rev. Pharmacool. Toxicol. 2010;50:295–322. doi: 10.1146/annurev.pharmtox.011008.145533. - DOI - PMC - PubMed
    1. Lavreysen H., Dautzenberg F.M. Therapeutic Potential of Group III Metabotropic Glutamate Receptors. Curr. Med. Chem. 2008;15:671–684. doi: 10.2174/092986708783885246. - DOI - PubMed
    1. Conn P.J., Lindsley C.W., Jones C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009;30:25–31. doi: 10.1016/j.tips.2008.10.006. - DOI - PMC - PubMed

MeSH terms

Substances

Grants and funding

LinkOut - more resources